BioAdvance News ImmunoGenesis Portfolio News

ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers

By WebmasterDecember 14, 2021November 1st, 2024No Comments

ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers

Clinical trials for ImmunoGenesis drug candidates to initiate in 2022

Previous PostAnnovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
Next PostRelmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option